EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Enrollment continues to exceed expectations in DURAVYU^™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage –

Read more at globenewswire.com